NCT06074029 2024-02-08
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Peking Union Medical College Hospital
Phase 1/2 Unknown
Clinical Trials
25 trialsNCT06202781 2024-01-12
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Chinese PLA General Hospital
Unknown
NCT05994456 2023-08-16
Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05913583 2023-06-22
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT05913661 2023-06-22
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05845268 2023-05-06
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT05048017 2023-03-29
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05777707 2023-03-21
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Beijing Friendship Hospital
Phase 1/2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05163483 2023-03-06
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05609695 2023-01-31
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Sun Yat-sen University
Unknown
NCT05509478 2022-09-10
LEADER-001
The First Hospital of Jilin University
Phase 2 Unknown
NCT05374252 2022-05-16
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT05371197 2022-05-12
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT04814043 2021-09-22
PLATIC
Sun Yat-sen University
Phase 2 Unknown
NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04913896 2021-06-04
CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy
The First Hospital of Jilin University
Unknown
NCT04814030 2021-04-23
AIPD-1
Sun Yat-sen University
Phase 2 Unknown
NCT04229355 2021-02-09
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 3 Unknown
NCT03989310 2020-12-23
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04004234 2019-07-09
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03311789 2017-10-17
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital
Phase 1/2 Unknown